{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=7&state=Ohio",
    "query": {
      "state": "Ohio",
      "city": "Columbus",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 10845,
    "total_pages": 1085,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=8&state=Ohio&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=6&state=Ohio&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T05:47:29.052Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01498289",
      "title": "S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Gastroesophageal Junction",
        "Esophageal Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "FOLFOX regimen",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 213,
      "start_date": "2012-02",
      "completion_date": "2019-09-19",
      "has_results": true,
      "last_update_posted_date": "2019-11-07",
      "last_synced_at": "2026-10-31T05:47:29.052Z",
      "location_count": 508,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Auburn, California + 320 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Burlingame",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01498289"
    },
    {
      "nct_id": "NCT04003389",
      "title": "A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hot Flashes"
      ],
      "interventions": [
        {
          "name": "fezolinetant",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 65 Years · Female only"
      },
      "enrollment_count": 1831,
      "start_date": "2019-07-10",
      "completion_date": "2022-01-04",
      "has_results": true,
      "last_update_posted_date": "2024-11-05",
      "last_synced_at": "2026-10-31T05:47:29.052Z",
      "location_count": 142,
      "location_summary": "Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 108 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Ensley",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04003389"
    },
    {
      "nct_id": "NCT01829568",
      "title": "Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma",
        "Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma",
        "Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma",
        "Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma",
        "Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma",
        "Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma",
        "Ann Arbor Stage III Grade 1 Follicular Lymphoma",
        "Ann Arbor Stage III Grade 2 Follicular Lymphoma",
        "Ann Arbor Stage III Grade 3 Follicular Lymphoma",
        "Ann Arbor Stage IV Grade 1 Follicular Lymphoma",
        "Ann Arbor Stage IV Grade 2 Follicular Lymphoma",
        "Ann Arbor Stage IV Grade 3 Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2013-06-26",
      "completion_date": "2027-06-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-10-31T05:47:29.052Z",
      "location_count": 7,
      "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01829568"
    },
    {
      "nct_id": "NCT05036135",
      "title": "A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "AV-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aerovate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 202,
      "start_date": "2021-12-02",
      "completion_date": "2024-08-09",
      "has_results": false,
      "last_update_posted_date": "2024-08-23",
      "last_synced_at": "2026-10-31T05:47:29.052Z",
      "location_count": 39,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05036135"
    },
    {
      "nct_id": "NCT02722525",
      "title": "Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiovascular Injury",
        "Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Exercise Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Perfusion Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Spectroscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 23,
      "start_date": "2014-12",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-10-31T05:47:29.052Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02722525"
    },
    {
      "nct_id": "NCT04130997",
      "title": "An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis (RMS)"
      ],
      "interventions": [
        {
          "name": "Ublituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TG Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1100,
      "start_date": "2019-11-18",
      "completion_date": "2032-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-10-31T05:47:29.052Z",
      "location_count": 19,
      "location_summary": "Pasadena, California • Denver, Colorado • Miami, Florida + 16 more",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Northbrook",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04130997"
    },
    {
      "nct_id": "NCT06374797",
      "title": "A Study of Auxora in Patients With AKI and Injurious Lung \"Crosstalk\"",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Auxora",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CalciMedica, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2024-07-01",
      "completion_date": "2026-04-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-31T05:47:29.052Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06374797"
    },
    {
      "nct_id": "NCT02854033",
      "title": "Alzheimer's Disease Neuroimaging Initiative 3",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mild Cognitive Impairment (MCI)",
        "Alzheimer's Disease (AD)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 1141,
      "start_date": "2016-12-02",
      "completion_date": "2024-05-28",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-10-31T05:47:29.052Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 42 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02854033"
    },
    {
      "nct_id": "NCT04804033",
      "title": "A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "BHV-3500 (zavegepant)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1753,
      "start_date": "2021-03-26",
      "completion_date": "2024-03-21",
      "has_results": true,
      "last_update_posted_date": "2025-03-27",
      "last_synced_at": "2026-10-31T05:47:29.052Z",
      "location_count": 116,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Canoga Park, California + 88 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04804033"
    },
    {
      "nct_id": "NCT00576758",
      "title": "GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "obinutuzumab (RO5072759)",
          "type": "DRUG"
        },
        {
          "name": "rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2008-01",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2014-08-19",
      "last_synced_at": "2026-10-31T05:47:29.052Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Denver, Colorado • Gainesville, Florida + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00576758"
    }
  ]
}